Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...
Main Authors: | Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2016
|
Similar Items
-
Evolving concepts in phases I and II drug development for Crohn's Disease
by: Jairath, V, et al.
Published: (2016) -
The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
by: Sandborn, W, et al.
Published: (2016) -
Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
by: Jairath, V, et al.
Published: (2016) -
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
by: D'Haens, G, et al.
Published: (2009) -
Biosimilars in IBD: hope or expectation?
by: Gecse, K, et al.
Published: (2013)